Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 438-445

  Vijayaraghavan, Arthi ^a   Efrusy, Molly B ^b   Göke, Burkhard ^c   Kirchner, Thomas ^d   Santas, Christopher C ^b   Goldberg, Richard M ^e  

^a McKesson   (United States)

^b Mazonson and Santas LLC   (United States)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

cost effectiveness; KRAS; metastatic colorectal carcinoma

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PANITUMUMAB;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; GERMANY; HIDDEN MARKOV MODEL; HUMAN; LIFE EXPECTANCY; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COST SAVINGS; COST-BENEFIT ANALYSIS; FLUOROURACIL; GENETIC TESTING; GERMANY; HUMANS; LEUCOVORIN; MARKOV CHAINS; MONTE CARLO METHOD; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; UNITED STATES;

EID: 84861631258     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26400     Document Type: Article

References (29)

1. Engstrom PF, Arnoletti JP, Benson AB 3rd., Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J Jr, et al. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 2009; 7: 778-831.
2. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rodel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, et al. [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol 2008; 46: 799-840.
3. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouche O, Landi B, Louvet C, Andre T, Bibeau F, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
4. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD,. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
5. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-7.
6. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S,. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-15.
7. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-72.
8. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-71.
9. Tejpar S, Peeters M, Humblet Y, Vermorken J, De Hertogh G, De Roock W, Nippgen J, von Heydebreck A, Stroh C, Van Cutsem E,: Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan- refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data) 2008 ASCO Annual Meeting, Chicago, IL 2008; 26.
10. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
12. Annemans L, Van Cutsem E, Humblet Y, Van Laethem JL, Bleiberg H,. Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan - a Belgian analysis. Acta Clin Belg 2007; 62: 419-25.
13. Krol M, Koopman M, Uyl-de Groot C, Punt CJ,. A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opin Pharmacother 2007; 8: 1313-28.
14. Starling N, Tilden D, White J, Cunningham D,. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. Br J Cancer 2007; 96: 206-12.
15. Tappenden P, Jones R, Paisley S, Carroll C,. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007; 11: 1-128, iii-iv.
16. Gold MR, Siegel JE, Russell LB, Weinstein MC,. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
17. Tol J, Dijkstra JR, Vink-Borger ME, Nagtegaal ID, Punt CJ, van Krieken JH, Ligtenberg MJ,. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med 2009; 14: 2122-2131.
18. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG,. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27: 1130-6.
19. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E,. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
20. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-21.
21. Meine Pflegeversicherung Stuttgart: Costs for a care facility in Stuttgart, the Städtische Altenheim Parkheim Berg, as of 8/17/08.
22. Schwabe U,. Neue Arzneimittel - kritisch betrachtet Therapie-Symposium 2008 Hamburg, Germany: Arzneimittelkommission der deutschen Ärzteschaft mit der Ärztekammer Hamburg und der KV Hamburg, 2008.
23. Ev. Altenhilfezentrum Meckmannshof Münster. Kostenübersicht Meckmannshof, vol. 2009. Münster, Germany: Evangelische Perthes-Werk, 2009.
24. Häusliche Pflege,: Das beinhaltet die häusliche Pflege, vol. 2009. Wiesbaden. VSP Financial Services
25. Schwabe U, Paffrath D,. Arzneiverordnungs-Report 2008: Aktuelle Daten, Kosten, Trends und Kommentareed. Heidelberg: Springer Medizin Verlag, 2008.
26. Table 1.1. Estimated New Cancer Cases and Deaths for 2009. In: sect-01-table.01.pdf, ed. Atlanta, Georgia: American Cancer Society, 2009.
27. Shankaran V, Bentrem DJ, Mulcahy MF, Bennett CL, Benson AB III,. Economic implications of Kras testing in metastatic colorectal cancer (mCRC). American Society of Clinical Oncology (ASCO) 2009 Gastrointestinal Cancers Symposium, vol. Abstract No: 298. San Francisco, CA, 2009.
28. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010; 304: 1812-20.
29. National Institute for Health and Clinical Excellence. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. London: National Institute for Health and Clinical Excellence, 2009.